A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.

ABSTRACT:

Background

Prevention of unnecessary biopsies and overtreatment of indolent disease remains a challenge in the management of prostate cancer. Novel non-invasive tests that can identify clinically significant (intermediate-risk and high-risk) diseases are needed to improve risk stratification and monitoring of prostate cancer patients. Here, we investigated a panel of six DNA methylation biomarkers in urine samples collected post-digital rectal exam from patients undergoing prostate biopsy, for their utility to guide decision making for diagnostic biopsy and early detection of aggressive prostate cancer.

Results

We recruited 408 patients in risk categories ranging from benign to low-, intermediate-, and high-risk prostate cancer from three international cohorts. Patients were

SUBMITTER: Zhao F 

PROVIDER: S-EPMC6260648 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature